Hangzhou Sumgen Biotech Co., Ltd. (hereinafter re......
On February 11, 2021, Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as Sumgen)announced that its self-developed CD47 targeting project SG404 was approved by FDA to preceed th
On Jan. 19, 2021, CNBG Sumgen Biopharmaceutical (Hangzhou) Co., Ltd. (hereinafter “CNBG Sumgen”) announced the successful completion of dosing in the first patient of the phase I clinical study of
On Nov. 9, 2020, CNBG Sumgen Biopharmaceutical (Hangzhou) Co., Ltd. (hereinafter “CNBG Sumgen”) announced that the IND application for its anti-CD47 product SG404 was approved by the Center for Dru
Hangzhou Sumgen Biotech Co., Ltd. (hereinafter “Sumgen”) has formally announced the completing of a 220 million RMB series B funding led by Addor Capital, co-led by Cowin Capital and Sinowisdom, an
On Jul. 24, 2020, Sumgen announced that the IND application for anti-CD38 human monoclonal antibody (SG301) was formally accepted by the Center for Drug Evaluation (CDE) of NMPA. This is the s
Hangzhou Sumgen Biotech Co., Ltd. (hereinafter “Sumgen) and China National Biotech Group (hereinafter “CNBG”) have recently announced the formal founding of a joint venture named CNBG Sumgen Biopha
he list of \"Top 50 Most Innovative Chinese Medical and Healthcare Enterprises 2019\" was recently released by Chuangye Zone, China\'s leading startup service platform, and Hangzhou Sumgen. Co
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044